Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Current price $1.23
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Sep 4, 26 |
Daily · Wilder smoothing
| Roth Capital |
| maintain |
| Buy |
| Buy |
| Jun 2, 26 | Roth Capital | maintain | Buy | Buy |
| May 28, 26 | Roth Capital | maintain | Buy | Buy |
| May 28, 26 | Leerink Partners | upgrade | Market Perform | Outperform |
| Apr 17, 26 | Roth Capital | maintain | Buy | Buy |
| Mar 28, 25 | Leerink Partners | downgrade | Outperform | Market Perform |
| Nov 1, 24 | Jones Trading | downgrade | Buy | Hold |
| Aug 19, 24 | HC Wainwright & Co. | maintain | Buy | Buy |
| Jun 5, 24 | HC Wainwright & Co. | maintain | Buy | Buy |
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 34.90 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 36.84 | Oscillator | Neutral |
| Williams %R (14) | -80.00 | Oscillator | Neutral |
| MACD (12, 26, 9) | -0.17 (Hist 0.02) | Oscillator | Buy |
| Average Directional Index (14) | 33.23 (+DI 15.7 / -DI 31.3) | Trend | Strong Sell |
| EMA 20 | 1.44 | MA | Strong Sell |
| SMA 20 | 1.41 | MA | Strong Sell |
| EMA 50 | 1.76 | MA | Strong Sell |
| SMA 50 | 1.87 | MA | Strong Sell |
| SMA 200 | 2.07 | MA | Strong Sell |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Jun 5, 26 | Zedelmayer Christine | officer: Sr. Vice President and COO | M-Exempt | 14,584 @ $0.785 | $11.45K |
| Jun 5, 26 | Zedelmayer Christine | officer: Sr. Vice President and COO | S-Sale | 14,584 @ $2.93 | $42.74K |
| Jun 5, 26 | Zedelmayer Christine | officer: Sr. Vice President and COO | M-Exempt | 14,584 @ $0.785 | $11.45K |
| Jun 4, 26 | Connelly Stephen | officer: President and CSO | S-Sale | 200,000 @ $3.16 | $632.8K |
| Jun 5, 26 | Connelly Stephen | officer: President and CSO | S-Sale | 30,975 @ $2.94 | $91.07K |
| May 28, 26 | Tom Penny | officer: Principal Accounting Officer | M-Exempt | 65,000 @ $0.785 | $51.02K |
| May 28, 26 | Tom Penny | officer: Principal Accounting Officer | S-Sale | 65,000 @ $2.95 | $191.8K |
| May 28, 26 | Tom Penny | officer: Principal Accounting Officer | M-Exempt | 65,000 @ $0.785 | $51.02K |
TTM vs. 5-year historical average (annual ratios)
| Metric | EQ | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -4.8x | -2.5x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -6.0x | EPS est. -0.21 | Elevated |
| Price / Book | 2.5x | 2.0x | Elevated |
| Price / Sales | — | 0.7x | Discount |
| EV / EBITDA | -1.2x | -1.6x | Discount |
| Return on equity | -41.2% | — | Weak |
| Gross margin | 0.0% | 60.0% | Below hist. |
| Debt / Equity | 0.01 | 0.12 | Conservative |
| Piotroski / Altman Z | 1/9 | Z 12.36 | Safe zone |
Discounted cash flow model
Stock news · updated daily
New preclinical data further characterizes EQ504's coordinated effects across epithelial and immune compartments in intestinal inflammation New preclinical data further characterizes EQ504's coordinated effects across epithelial and immune compartments in intestinal inflammation
On track to initiate dosing by early November 2026; topline Phase 1 proof-of-mechanism data anticipated approximately six months following study initiation
New preclinical data further characterize EQ504's effects on epithelial barrier repair and immune regulation New preclinical data further characterize EQ504's effects on epithelial barrier repair and immune regulation
Equillium (NASDAQ: EQ) Chief Scientific Officer Stephen Connelly outlined the company's plans to advance its lead programs, including an oral aryl hydrocarbon receptor, or AhR, modulator for ulcerative colitis and an oral bispecific peptide for celiac disease, during a fireside chat. Connelly said the company, founded in 2017 and public since 2018, has focused on developing
Equillium NASDAQ: EQ Chief Scientific Officer Stephen Connelly outlined the company's plans to advance its lead programs, including an oral aryl hydrocarbon receptor, or AhR, modulator for ulcerative colitis and an oral bispecific peptide for celiac disease, during a fireside chat.
LA JOLLA, Calif., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will be participating in a fireside chat at Stifel's 2026 Virtual Immunology and Inflammation Forum on Wednesday, September 23, 2026 at 12:00pm EDT.
Australian miner EQ Resources said on Tuesday it would take a 10% stake in a joint venture with Nasdaq-listed Elmet Group and Blue Moon Metals to restart the Springer tungsten project in Nevada.
LA JOLLA, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will participate in the following upcoming investor conferences: Cantor Global Healthcare Conference 2026 Format: Fireside Chat & 1x1 MeetingsDate: Wednesday, September 9, 2026Time: 9:45 AM EDTWebcast Link: Here H.C.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 13, 2026 | -0.05 | -0.04 | Beat 25.9% | — |
| May 13, 2026 | -0.04 | -0.06 | Miss -50.0% | — |
| Mar 25, 2026 | -0.07 | -0.04 | Beat 42.9% | — |
| Nov 13, 2025 | -0.14 | -0.06 | Beat 57.1% | — |
| Aug 14, 2025 | -0.14 | -0.16 | Miss -14.3% | — |
| May 14, 2025 | -0.23 | -0.24 | Miss -4.3% | — |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 8-K | Oct 5, 2026 | 2026-10-05 17:06:37 | View |
| 10-Q | Aug 13, 2026 | 2026-08-13 16:15:34 | View |
| SC 13G | Aug 13, 2026 | 2026-08-13 16:11:28 | View |
| 8-K | Aug 13, 2026 | 2026-08-13 16:10:16 | View |
| SC 13G/A | Aug 12, 2026 | 2026-08-12 12:11:42 | View |
| 4 | Jun 5, 2026 | 2026-06-05 16:42:58 | View |
| 4 | Jun 5, 2026 | 2026-06-05 16:42:00 | View |
| 4 | May 29, 2026 | 2026-05-29 18:28:50 | View |
| 4 | May 29, 2026 | 2026-05-29 18:27:09 | View |
| 4 | May 29, 2026 | 2026-05-29 18:25:11 | View |
Proxy statement (DEF 14A) disclosures